Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

Trial StartVY1706Positive

AI Analysis

Summary

Voyager Therapeutics reported that a single IV dose of VY1706 was well tolerated and reduced tau in a 6-month GLP toxicology study, with clinical trial initiation in Alzheimer's Disease expected in H2 2026.

Clinical Trial Data

Outcome Details

Single IV dose well tolerated; reduced tau in 6-month GLP toxicology study

Importance:6/10

Sentiment:

0.70

Alzheimer's DiseaseTauVY1706GLP ToxicologyClinical Trial Initiation

Related Companies

$VYGR

Read the original article

Published by yahoo_finance on July 13, 2026 12:01 PM

Read Original